Scholar Rock Holding Corporation (NASDAQ: SRRK) Stock Competitors & Peer Comparison
See SRRK's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for SRRK and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SRRK | $45.85 | -3.06% | 5.5B | -12.77 | -$3.59 | N/A |
| VRTX | $470.72 | -1.34% | 119.5B | 25.01 | $18.82 | N/A |
| REGN | $759.24 | -0.44% | 78.2B | 16.64 | $45.63 | +0.48% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $830.79 | -2.70% | 51.7B | 74.98 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $182.45 | -2.71% | 38.8B | -25.81 | -$7.07 | N/A |
| RVMDW | $8.84 | -7.58% | 36.8B | -2.13 | -$4.15 | N/A |
| ONC | $313.77 | -0.71% | 33.5B | 70.19 | $4.47 | N/A |
| ALNY | $220.33 | +7.21% | 29.5B | 39.70 | $5.55 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
SRRK vs VRTX Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, VRTX has a market cap of 119.5B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while VRTX trades at $470.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas VRTX's P/E ratio is 25.01. In terms of profitability, SRRK's ROE is -1.64%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, SRRK is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
SRRK vs REGN Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, REGN has a market cap of 78.2B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while REGN trades at $759.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas REGN's P/E ratio is 16.64. In terms of profitability, SRRK's ROE is -1.64%, compared to REGN's ROE of +0.18%. Regarding short-term risk, SRRK is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
SRRK vs VRNA Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas VRNA's P/E ratio is -102.80. In terms of profitability, SRRK's ROE is -1.64%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, SRRK is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
SRRK vs ARGX Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, ARGX has a market cap of 51.7B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while ARGX trades at $830.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas ARGX's P/E ratio is 74.98. In terms of profitability, SRRK's ROE is -1.64%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, SRRK is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
SRRK vs SGEN Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas SGEN's P/E ratio is -57.19. In terms of profitability, SRRK's ROE is -1.64%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, SRRK is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
SRRK vs RVMD Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, RVMD has a market cap of 38.8B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while RVMD trades at $182.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas RVMD's P/E ratio is -25.81. In terms of profitability, SRRK's ROE is -1.64%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, SRRK is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
SRRK vs RVMDW Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, RVMDW has a market cap of 36.8B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while RVMDW trades at $8.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas RVMDW's P/E ratio is -2.13. In terms of profitability, SRRK's ROE is -1.64%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, SRRK is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check RVMDW's competition here
BeOne Medicines AG (NASDAQ: ONC)
SRRK vs ONC Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, ONC has a market cap of 33.5B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while ONC trades at $313.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas ONC's P/E ratio is 70.19. In terms of profitability, SRRK's ROE is -1.64%, compared to ONC's ROE of +0.12%. Regarding short-term risk, SRRK is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
SRRK vs ALNY Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, ALNY has a market cap of 29.5B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while ALNY trades at $220.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas ALNY's P/E ratio is 39.70. In terms of profitability, SRRK's ROE is -1.64%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, SRRK is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
SRRK vs ROIV Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, ROIV has a market cap of 24.1B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while ROIV trades at $33.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas ROIV's P/E ratio is -34.25. In terms of profitability, SRRK's ROE is -1.64%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, SRRK is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
SRRK vs INCY Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, INCY has a market cap of 24B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while INCY trades at $118.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas INCY's P/E ratio is 15.92. In terms of profitability, SRRK's ROE is -1.64%, compared to INCY's ROE of +0.30%. Regarding short-term risk, SRRK is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
SRRK vs BNTX Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, BNTX has a market cap of 23.3B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while BNTX trades at $92.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas BNTX's P/E ratio is -19.97. In terms of profitability, SRRK's ROE is -1.64%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, SRRK is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
SRRK vs UTHR Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, UTHR has a market cap of 21.9B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while UTHR trades at $516.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas UTHR's P/E ratio is 19.06. In terms of profitability, SRRK's ROE is -1.64%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, SRRK is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check UTHR's competition here
Moderna, Inc. (NASDAQ: MRNA)
SRRK vs MRNA Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, MRNA has a market cap of 21.9B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while MRNA trades at $55.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas MRNA's P/E ratio is -6.77. In terms of profitability, SRRK's ROE is -1.64%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, SRRK is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check MRNA's competition here
Insmed Incorporated (NASDAQ: INSM)
SRRK vs INSM Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, INSM has a market cap of 21.3B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while INSM trades at $98.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas INSM's P/E ratio is -17.12. In terms of profitability, SRRK's ROE is -1.64%, compared to INSM's ROE of -1.30%. Regarding short-term risk, SRRK is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check INSM's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
SRRK vs BGNE Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas BGNE's P/E ratio is -22.55. In terms of profitability, SRRK's ROE is -1.64%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, SRRK is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
SRRK vs DNA-WT Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, SRRK's ROE is -1.64%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, SRRK is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check DNA-WT's competition here
Genmab A/S (NASDAQ: GMAB)
SRRK vs GMAB Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, GMAB has a market cap of 17.6B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while GMAB trades at $28.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas GMAB's P/E ratio is 20.63. In terms of profitability, SRRK's ROE is -1.64%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, SRRK is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check GMAB's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
SRRK vs NBIX Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, NBIX has a market cap of 16.7B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while NBIX trades at $166.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas NBIX's P/E ratio is 24.02. In terms of profitability, SRRK's ROE is -1.64%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, SRRK is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
SRRK vs JAZZ Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, JAZZ has a market cap of 15.8B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while JAZZ trades at $251.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas JAZZ's P/E ratio is 19.56. In terms of profitability, SRRK's ROE is -1.64%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, SRRK is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
SRRK vs BBIO Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, BBIO has a market cap of 15.7B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while BBIO trades at $79.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas BBIO's P/E ratio is -21.38. In terms of profitability, SRRK's ROE is -1.64%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, SRRK is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
SRRK vs ASND Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, ASND has a market cap of 15.1B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while ASND trades at $243.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas ASND's P/E ratio is -100.60. In terms of profitability, SRRK's ROE is -1.64%, compared to ASND's ROE of -56.42%. Regarding short-term risk, SRRK is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
SRRK vs EXEL Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, EXEL has a market cap of 13.8B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while EXEL trades at $55.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas EXEL's P/E ratio is 16.49. In terms of profitability, SRRK's ROE is -1.64%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, SRRK is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check EXEL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
SRRK vs KRTX Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas KRTX's P/E ratio is -28.09. In terms of profitability, SRRK's ROE is -1.64%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, SRRK is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check KRTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
SRRK vs ARWR Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, ARWR has a market cap of 12.1B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while ARWR trades at $86.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas ARWR's P/E ratio is -40.00. In terms of profitability, SRRK's ROE is -1.64%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, SRRK is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check ARWR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
SRRK vs BMRN Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while BMRN trades at $60.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas BMRN's P/E ratio is 28.84. In terms of profitability, SRRK's ROE is -1.64%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, SRRK is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check BMRN's competition here
Bio-Techne Corporation (NASDAQ: TECH)
SRRK vs TECH Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while TECH trades at $72.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas TECH's P/E ratio is 37.19. In terms of profitability, SRRK's ROE is -1.64%, compared to TECH's ROE of +0.05%. Regarding short-term risk, SRRK is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
SRRK vs RNAM Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas RNAM's P/E ratio is -17.39. In terms of profitability, SRRK's ROE is -1.64%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, SRRK is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check RNAM's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
SRRK vs MDGL Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, MDGL has a market cap of 11.1B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while MDGL trades at $482.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas MDGL's P/E ratio is -37.66. In terms of profitability, SRRK's ROE is -1.64%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, SRRK is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check MDGL's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
SRRK vs AXSM Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, AXSM has a market cap of 10.9B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while AXSM trades at $211.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas AXSM's P/E ratio is -55.10. In terms of profitability, SRRK's ROE is -1.64%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, SRRK is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check AXSM's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
SRRK vs SMMT Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, SMMT has a market cap of 10.4B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while SMMT trades at $13.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas SMMT's P/E ratio is -8.15. In terms of profitability, SRRK's ROE is -1.64%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, SRRK is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check SMMT's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
SRRK vs HALO Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, HALO has a market cap of 9.8B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while HALO trades at $82.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas HALO's P/E ratio is 17.81. In terms of profitability, SRRK's ROE is -1.64%, compared to HALO's ROE of +1.26%. Regarding short-term risk, SRRK is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check HALO's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
SRRK vs RXDX Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas RXDX's P/E ratio is -56.47. In terms of profitability, SRRK's ROE is -1.64%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, SRRK is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check RXDX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
SRRK vs CYTK Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, CYTK has a market cap of 9.5B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while CYTK trades at $76.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas CYTK's P/E ratio is -13.11. In terms of profitability, SRRK's ROE is -1.64%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, SRRK is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check CYTK's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
SRRK vs KRYS Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, KRYS has a market cap of 9.2B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while KRYS trades at $312.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas KRYS's P/E ratio is 41.79. In terms of profitability, SRRK's ROE is -1.64%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, SRRK is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check KRYS's competition here
Abivax S.A. (NASDAQ: ABVX)
SRRK vs ABVX Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while ABVX trades at $124.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas ABVX's P/E ratio is -65.41. In terms of profitability, SRRK's ROE is -1.64%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, SRRK is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check ABVX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
SRRK vs NUVL Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas NUVL's P/E ratio is -21.79. In terms of profitability, SRRK's ROE is -1.64%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, SRRK is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check NUVL's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
SRRK vs IONS Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, IONS has a market cap of 9.1B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while IONS trades at $54.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas IONS's P/E ratio is -31.68. In terms of profitability, SRRK's ROE is -1.64%, compared to IONS's ROE of -1.11%. Regarding short-term risk, SRRK is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check IONS's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
SRRK vs CRNX Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while CRNX trades at $83.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas CRNX's P/E ratio is -16.33. In terms of profitability, SRRK's ROE is -1.64%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, SRRK is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check CRNX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
SRRK vs IMGN Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas IMGN's P/E ratio is -111.55. In terms of profitability, SRRK's ROE is -1.64%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, SRRK is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check IMGN's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
SRRK vs PRAX Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, PRAX has a market cap of 8.5B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while PRAX trades at $305.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas PRAX's P/E ratio is -22.85. In terms of profitability, SRRK's ROE is -1.64%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, SRRK is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check PRAX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
SRRK vs PTGX Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, PTGX has a market cap of 8.5B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while PTGX trades at $132.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas PTGX's P/E ratio is -73.08. In terms of profitability, SRRK's ROE is -1.64%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, SRRK is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check PTGX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
SRRK vs BPMC Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas BPMC's P/E ratio is -51.58. In terms of profitability, SRRK's ROE is -1.64%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, SRRK is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check BPMC's competition here
Alkermes plc (NASDAQ: ALKS)
SRRK vs ALKS Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, ALKS has a market cap of 8.3B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while ALKS trades at $49.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas ALKS's P/E ratio is 52.14. In terms of profitability, SRRK's ROE is -1.64%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, SRRK is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check ALKS's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
SRRK vs APGE Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while APGE trades at $134.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas APGE's P/E ratio is -30.97. In terms of profitability, SRRK's ROE is -1.64%, compared to APGE's ROE of -0.33%. Regarding short-term risk, SRRK is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check APGE's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
SRRK vs KYMR Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, KYMR has a market cap of 8.3B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while KYMR trades at $100.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas KYMR's P/E ratio is -28.42. In terms of profitability, SRRK's ROE is -1.64%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, SRRK is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check KYMR's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
SRRK vs SYRE Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, SYRE has a market cap of 8.2B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while SYRE trades at $94.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas SYRE's P/E ratio is -45.64. In terms of profitability, SRRK's ROE is -1.64%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, SRRK is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check SYRE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
SRRK vs CERE Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas CERE's P/E ratio is -16.47. In terms of profitability, SRRK's ROE is -1.64%, compared to CERE's ROE of -0.72%. Regarding short-term risk, SRRK is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check CERE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
SRRK vs IMVT Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, IMVT has a market cap of 7.9B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while IMVT trades at $38.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas IMVT's P/E ratio is -14.42. In terms of profitability, SRRK's ROE is -1.64%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, SRRK is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check IMVT's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
SRRK vs PCVX Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, PCVX has a market cap of 7.7B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while PCVX trades at $53.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas PCVX's P/E ratio is -7.78. In terms of profitability, SRRK's ROE is -1.64%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, SRRK is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check PCVX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
SRRK vs IBRX Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while IBRX trades at $7.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas IBRX's P/E ratio is -8.41. In terms of profitability, SRRK's ROE is -1.64%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, SRRK is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check IBRX's competition here
Metsera, Inc. (NASDAQ: MTSR)
SRRK vs MTSR Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas MTSR's P/E ratio is -23.58. In terms of profitability, SRRK's ROE is -1.64%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, SRRK is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check MTSR's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
SRRK vs TGTX Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, TGTX has a market cap of 7.1B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while TGTX trades at $46.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas TGTX's P/E ratio is 15.87. In terms of profitability, SRRK's ROE is -1.64%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, SRRK is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check TGTX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
SRRK vs RYTM Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, RYTM has a market cap of 7.1B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while RYTM trades at $102.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas RYTM's P/E ratio is -32.84. In terms of profitability, SRRK's ROE is -1.64%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, SRRK is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check RYTM's competition here
Merus N.V. (NASDAQ: MRUS)
SRRK vs MRUS Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas MRUS's P/E ratio is -17.05. In terms of profitability, SRRK's ROE is -1.64%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, SRRK is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
SRRK vs ACLX Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas ACLX's P/E ratio is -28.27. In terms of profitability, SRRK's ROE is -1.64%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, SRRK is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check ACLX's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
SRRK vs COGT Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, COGT has a market cap of 6.6B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while COGT trades at $38.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas COGT's P/E ratio is -18.42. In terms of profitability, SRRK's ROE is -1.64%, compared to COGT's ROE of -0.83%. Regarding short-term risk, SRRK is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check COGT's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
SRRK vs RETA Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas RETA's P/E ratio is -66.29. In terms of profitability, SRRK's ROE is -1.64%, compared to RETA's ROE of +0.47%. Regarding short-term risk, SRRK is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check RETA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
SRRK vs MIRM Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, MIRM has a market cap of 6.4B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while MIRM trades at $104.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas MIRM's P/E ratio is -7.68. In terms of profitability, SRRK's ROE is -1.64%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, SRRK is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check MIRM's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
SRRK vs CNTA Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas CNTA's P/E ratio is -22.63. In terms of profitability, SRRK's ROE is -1.64%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, SRRK is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check CNTA's competition here
Belite Bio, Inc (NASDAQ: BLTE)
SRRK vs BLTE Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, BLTE has a market cap of 6.2B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while BLTE trades at $154.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas BLTE's P/E ratio is -82.78. In terms of profitability, SRRK's ROE is -1.64%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, SRRK is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check BLTE's competition here
Erasca, Inc. (NASDAQ: ERAS)
SRRK vs ERAS Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, ERAS has a market cap of 6.2B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while ERAS trades at $17.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas ERAS's P/E ratio is -19.18. In terms of profitability, SRRK's ROE is -1.64%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, SRRK is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check ERAS's competition here
CG Oncology Inc. (NASDAQ: CGON)
SRRK vs CGON Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, CGON has a market cap of 6.1B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while CGON trades at $69.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas CGON's P/E ratio is -29.68. In terms of profitability, SRRK's ROE is -1.64%, compared to CGON's ROE of -0.23%. Regarding short-term risk, SRRK is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check CGON's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
SRRK vs XENE Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, XENE has a market cap of 6B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while XENE trades at $62.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas XENE's P/E ratio is -13.25. In terms of profitability, SRRK's ROE is -1.64%, compared to XENE's ROE of -0.49%. Regarding short-term risk, SRRK is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check XENE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
SRRK vs LGND Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, LGND has a market cap of 5.9B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while LGND trades at $292.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas LGND's P/E ratio is 35.02. In terms of profitability, SRRK's ROE is -1.64%, compared to LGND's ROE of +0.16%. Regarding short-term risk, SRRK is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check LGND's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
SRRK vs PTCT Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, PTCT has a market cap of 5.7B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while PTCT trades at $68.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas PTCT's P/E ratio is -29.23. In terms of profitability, SRRK's ROE is -1.64%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, SRRK is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check PTCT's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
SRRK vs CDTX Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas CDTX's P/E ratio is -19.77. In terms of profitability, SRRK's ROE is -1.64%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, SRRK is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
SRRK vs ABCM Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, SRRK's ROE is -1.64%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, SRRK is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
SRRK vs ISEE Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas ISEE's P/E ratio is -22.44. In terms of profitability, SRRK's ROE is -1.64%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, SRRK is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
SRRK vs APLS Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas APLS's P/E ratio is 38.35. In terms of profitability, SRRK's ROE is -1.64%, compared to APLS's ROE of +0.40%. Regarding short-term risk, SRRK is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check APLS's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
SRRK vs TVTX Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, TVTX has a market cap of 5.1B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while TVTX trades at $54.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas TVTX's P/E ratio is -249.77. In terms of profitability, SRRK's ROE is -1.64%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, SRRK is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check TVTX's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
SRRK vs CRSP Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, CRSP has a market cap of 4.8B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while CRSP trades at $49.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas CRSP's P/E ratio is -9.70. In terms of profitability, SRRK's ROE is -1.64%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, SRRK is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check CRSP's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
SRRK vs TERN Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas TERN's P/E ratio is -51.41. In terms of profitability, SRRK's ROE is -1.64%, compared to TERN's ROE of -0.20%. Regarding short-term risk, SRRK is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check TERN's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
SRRK vs DYN Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, DYN has a market cap of 4.7B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while DYN trades at $25.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas DYN's P/E ratio is -7.84. In terms of profitability, SRRK's ROE is -1.64%, compared to DYN's ROE of -0.64%. Regarding short-term risk, SRRK is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check DYN's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
SRRK vs CAI Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, CAI has a market cap of 4.6B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while CAI trades at $16.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas CAI's P/E ratio is -89.77. In terms of profitability, SRRK's ROE is -1.64%, compared to CAI's ROE of +0.06%. Regarding short-term risk, SRRK is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check CAI's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
SRRK vs DFTX Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, DFTX has a market cap of 4.6B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while DFTX trades at $41.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas DFTX's P/E ratio is N/A. In terms of profitability, SRRK's ROE is -1.64%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, SRRK is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check DFTX's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
SRRK vs FOLD Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas FOLD's P/E ratio is -161.00. In terms of profitability, SRRK's ROE is -1.64%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, SRRK is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
SRRK vs AKRO Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas AKRO's P/E ratio is -14.57. In terms of profitability, SRRK's ROE is -1.64%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, SRRK is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
SRRK vs ALPN Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas ALPN's P/E ratio is -101.52. In terms of profitability, SRRK's ROE is -1.64%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, SRRK is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check ALPN's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
SRRK vs DNTH Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, DNTH has a market cap of 4.4B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while DNTH trades at $106.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas DNTH's P/E ratio is -25.67. In terms of profitability, SRRK's ROE is -1.64%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, SRRK is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check DNTH's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
SRRK vs ACAD Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while ACAD trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas ACAD's P/E ratio is 12.55. In terms of profitability, SRRK's ROE is -1.64%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, SRRK is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check ACAD's competition here
Celcuity Inc. (NASDAQ: CELC)
SRRK vs CELC Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, CELC has a market cap of 4.3B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while CELC trades at $87.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas CELC's P/E ratio is -22.49. In terms of profitability, SRRK's ROE is -1.64%, compared to CELC's ROE of -2.45%. Regarding short-term risk, SRRK is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check CELC's competition here
Veradermics, Incorporated (NYSE: MANE)
SRRK vs MANE Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, MANE has a market cap of 4.3B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while MANE trades at $101.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas MANE's P/E ratio is -32.44. In terms of profitability, SRRK's ROE is -1.64%, compared to MANE's ROE of -0.84%. Regarding short-term risk, SRRK is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check MANE's competition here
Opthea Limited (NASDAQ: OPT)
SRRK vs OPT Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas OPT's P/E ratio is -1.52. In terms of profitability, SRRK's ROE is -1.64%, compared to OPT's ROE of +1.18%. Regarding short-term risk, SRRK is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
SRRK vs PRTC Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas PRTC's P/E ratio is -3.78. In terms of profitability, SRRK's ROE is -1.64%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, SRRK is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check PRTC's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
SRRK vs ELVN Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, ELVN has a market cap of 4.1B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while ELVN trades at $58.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas ELVN's P/E ratio is -34.75. In terms of profitability, SRRK's ROE is -1.64%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, SRRK is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check ELVN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
SRRK vs EWTX Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, EWTX has a market cap of 4.1B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while EWTX trades at $38.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas EWTX's P/E ratio is -23.12. In terms of profitability, SRRK's ROE is -1.64%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, SRRK is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check EWTX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
SRRK vs MRTX Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas MRTX's P/E ratio is -4.82. In terms of profitability, SRRK's ROE is -1.64%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, SRRK is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check MRTX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
SRRK vs CPRX Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas CPRX's P/E ratio is 12.30. In terms of profitability, SRRK's ROE is -1.64%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, SRRK is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check CPRX's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
SRRK vs VKTX Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while VKTX trades at $32.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas VKTX's P/E ratio is -7.88. In terms of profitability, SRRK's ROE is -1.64%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, SRRK is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check VKTX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
SRRK vs RYZB Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas RYZB's P/E ratio is -57.86. In terms of profitability, SRRK's ROE is -1.64%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, SRRK is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
SRRK vs CBAY Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas CBAY's P/E ratio is -32.81. In terms of profitability, SRRK's ROE is -1.64%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, SRRK is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check CBAY's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
SRRK vs ADPT Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, ADPT has a market cap of 3.7B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while ADPT trades at $23.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas ADPT's P/E ratio is -42.80. In terms of profitability, SRRK's ROE is -1.64%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, SRRK is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check ADPT's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
SRRK vs DNLI Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while DNLI trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas DNLI's P/E ratio is -8.04. In terms of profitability, SRRK's ROE is -1.64%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, SRRK is more volatile compared to DNLI. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check DNLI's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
SRRK vs ORKA Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, ORKA has a market cap of 3.5B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while ORKA trades at $94.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas ORKA's P/E ratio is -48.86. In terms of profitability, SRRK's ROE is -1.64%, compared to ORKA's ROE of -0.26%. Regarding short-term risk, SRRK is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check ORKA's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
SRRK vs SWTX Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas SWTX's P/E ratio is -13.78. In terms of profitability, SRRK's ROE is -1.64%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, SRRK is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check SWTX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
SRRK vs LEGN Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, LEGN has a market cap of 3.5B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while LEGN trades at $19.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas LEGN's P/E ratio is -27.96. In terms of profitability, SRRK's ROE is -1.64%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, SRRK is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check LEGN's competition here
Arcus Biosciences, Inc. (NYSE: RCUS)
SRRK vs RCUS Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, RCUS has a market cap of 3.5B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while RCUS trades at $27.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas RCUS's P/E ratio is -8.48. In terms of profitability, SRRK's ROE is -1.64%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, SRRK is less volatile compared to RCUS. This indicates lower risk in terms of short-term price fluctuations for SRRK.Check RCUS's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
SRRK vs TLX Comparison August 2026
Scholar Rock Holding Corporation (NASDAQ: SRRK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRRK stands at 5.5B. In comparison, TLX has a market cap of 3.4B. Regarding current trading prices, SRRK is priced at $45.85 on the NASDAQ, while TLX trades at $10.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRRK currently has a P/E ratio of -12.77, whereas TLX's P/E ratio is -544.57. In terms of profitability, SRRK's ROE is -1.64%, compared to TLX's ROE of -0.02%. Regarding short-term risk, SRRK is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for SRRK.Check TLX's competition here